From Health Tech to Nature Tech
From health tech to Nature Tech, BNP Paribas has a key role to play in investing in and supporting impact companies who are actively changing how we think about health for humans, the environment and the world at large. Solutions that combine technology and health converge around a shared objective: building systems that are both efficient and regenerative, capable of sustaining long-term health across human and natural environments.
Investing in Health Tech Solutions to Improve Human Health and Medical Care at Scale
Today, the field of health tech is transforming medical care with solutions that are leveraging technology such as generative AI and connected devices that can collect, send and receive data in real time. The use of technology to address human health concerns is playing an increasingly vital role in enhancing efficiency, safety and convenience for patient care. For example, Lifeaz and Synapse Medicine are two French health tech companies supported by the Group whose transformative tech-driven solutions are democratising and simplifying what medical care looks like in our daily lives.
Tech & Human Health: Lifeaz’s Connected Defibrillator and Digital Platform
Every year, tens of thousands of people die from cardiac arrests that may have been prevented had intervention and help arrived sooner. The French health tech start-up Lifeaz aims to address this critical gap in immediate care with its simple, accessible solution built on three technological pillars:
a fully automated defibrillator that’s manufactured in Normandy, France and designed specifically for individual use, unlike other defibrillators that are often only available in public spaces and at companies legally required to supply this equipment;
connected maintenance with real-time monitoring and remote maintenance by the Lifeaz team without the need for annual in-person maintenance with a technician;
and life-saving trainings accessible to all so everyone is equipped to act in the event of a cardiac arrest (via the Lifeaz application, videoconference workshops and in-person trainings).
Lifeaz a levé 13 millions d'euros avec l'ambition de sauver 1 000 vies dans les cinq prochaines années
In February 2026, Lifeaz raised 13 million euros with the support of BNP Paribas to scale its operations and accelerate the deployment of its connected defibrillators across Europe. The Group invested in equity in the health tech company as part of its 200 million euro impact investing envelope, which is co-managed by the Group’s Positive Impact & Inclusion Business Accelerator (PIIBA) and BNP Paribas Asset Management.
Rather than viewing the defibrillator as an isolated piece of equipment, Lifeaz offers a more comprehensive approach combining a connected device, remote monitoring and awareness tools, all based on an affordable service model. The impact company not only improves the emergency response time and efficiency of immediate care while waiting for medical first responders but also makes it easier for as many people as possible to access and use defibrillators.
- Grow its customer base from 25,000 to 100,000 clients
- Go from 100 to 1,000 lives saved thanks to its connected defibrillators
- Scale its development across Europe
- Expand its teams to support this new phase of growth
ChangeNOW 2026: BNP Paribas stand featuring Les Alchimistes, Lifeaz, Teserrac, Willow.
ChangeNOW 2026: BNP Paribas, the bank for impact companies driving positive change!
Most recently, Lifeaz was among the impact companies featured at BNP Paribas’ stand at ChangeNOW 2026, the world’s largest event for solutions that drive positive change for the planet. Other notable companies supported by the Group that were showcased among the 1,000+ solutions featured in stands and workshops over the course of the three-day event included: les Alchimistes, Klim, Kumulus Water, Le Printemps de Terres, Meet My Mama, Teserrac, Willow and Woodoo.
Tech & Human Health: Synapse Medicine’s MedGPT.fr, a generative AI tool for medical professionals
Winner of the 2025 My Com For Impact “Grand Laureat” prize announced by BNP Paribas and Publicis France last December, Synapse Medicine is another example of a health tech company changing the medical landscape by using artificial intelligence to enhance clinical decision-making and improve medical prescription safety. Most notably, the start-up developed MedGPT.fr, a generative AI tool designed specifically for the medical sector currently used by more than 150,000 medical professionals in France.
Concretely, MedGPT.fr aims to help medical professionals in France provide more timely, accurate delivery of prescriptions to enhance patient care and free up time for other medical tasks. The Group’s subsidiary BNP Paribas Développement, took a stake in Synapse Medicine in 2018 and continues to support the company’s growth.
Introducing a “One Health” Approach: Investing in Nature Tech Solutions to Improve Environmental Health and Restore Ecosystems
If health tech addresses human health directly, the field of Nature Tech expands the scope by tackling the environmental systems that underpin it. More specifically, Nature Tech and biotechnology are leveraging natural processes to restore ecosystems, improve agricultural resilience, and reduce environmental impact.
Tech & Environmental Health: Mycophyto’s biotech solution harnesses the power of mycorrhizal mushrooms “to preserve health of soils and the health of human beings”
Mycophyto's unique approach combines biotechnology, natural soil symbiosis, and artificial intelligence to develop organic solutions to sustainably regenerate soil and strengthen crop resilience. More specifically, the company develops biostimulants and biopesticides derived from arbuscular mycorrhizal fungi (AMF), microscopic organisms that form symbiotic relationships with plants. Rather than replacing ecosystems with synthetic solutions, it enhances natural processes with cutting-edge technology, making it a key example of Nature Tech.
Mycophyto’s innovative biostimulants and biopesticides aim to enhance soil health, improve plant resilience, promote regenerative agriculture and ultimately support the health of human beings with more sustainable food production that addresses challenges to food sovereignty. These innovative biotech products are designed to integrate seamlessly into existing agricultural systems, providing farmers with a practical and effective way to improve crop yields. Mycophyto transforms the challenges of climate change and the agricultural transition into concrete opportunities for farmers, enabling them to: save up to 20% in water usage and 30% in fertiliser, and increase yields by up to 50%. In this sense, the innovative impact company contributes to the sustainability and resilience of the soil, while also reducing the use of inputs that can generate pollution.
Mycophyto raises 16 million euros in Series A funding with support from BNP Paribas
In January 2026, BNP Paribas supported Mycophyto in raising 16 million euros in Series A Funding to scale production of its tech-driven biological solutions. This capital will enable the biotech company to build its first facility to scale to industrial production and continue its international expansion in Spain and Morocco and establish new distribution channels in the Côte d’Ivoire and Benelux.
In addition to Mycophyto, BNP Paribas is dedicated to investing in Nature Tech companies like Kayrros, Klim and Printemps des Terres and promoting regenerative agricultural practices with clients such as McCain in Poland.
Financing the Future of Health and Scaling Innovation in a Rapidly Changing World: A “One Health” Approach
As global challenges become more complex, the need for integrated solutions has never been greater. Technology offers powerful tools to address these challenges—but scaling them requires strong financial support. It is here that financial institutions and banks like BNP Paribas have a critical role to play in investing in technology-driven impact companies that are driving positive health outcomes at scale.
By investing in tech-driven companies like Lifeaz, Synapse Medicine, Mycophyto and Klim (just to name a few!) the Group aims to accelerate innovative solutions that protect and improve all types of health. This approach reflects a broader ambition for public and private actors to support the principles of “One Health”, a concept that recognises that human, animal and environmental health are all interconnected. In this context, investing in and supporting impact companies is not just about supporting innovation—it is about envisioning and enabling a future where human, animal and environmental health are addressed together.
"The One Health concept makes it possible to overcome siloed interpretations of ESG challenges in favour of an integrated and prevention-oriented approach. One Health can act as both a compass to address the common challenges related to the health of humans, animals and ecosystems, and as a lever for the mobilisation of the public and private sectors.”
